# of Displayed Technologies: 9 / 9

Applied Category Filter (Click To Remove): Therapeutics


Categories

mRNA sequence engineering and uses thereof
TS-045448 — Maximized mRNA lifespan and translation for mRNA-based therapy applications.
Many diseases emerge from irregularities that occur during protein synthesis. While limited therapies exist to deliver mature proteins to compensate for these errors, protein therapy by direct protein delivery has limited efficiency. This is due to difficulty in controlling the volume of delivered…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Zeng, Chunxi
  • Licensing Officer: Dahlman, Jason "Jay"

Improving immunotherapy with mRNA delivery
TS-045426 — The central mission of cancer immunotherapy treatments is to aid the immune system in detecting and degrading cancer cells. For twenty years, the use of monoclonal antibodies (mAbs) as anti-tumor drugs has been successful in managing cancer disease and increasing patient lifespan. These treatments…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Li, Wenqing; Zhang, Chengxiang
  • Licensing Officer: Dahlman, Jason "Jay"

Live vaccine candidate for Chagas disease
TS-044084 — Trypanosoma cruzi is a protozoan parasite that causes Chagas disease, a PRV-eligible disease that is the leading cause of heart failure in Latin America. Due to migration of infected hosts from endemic regions, Chagas disease is also a growing public health concern in the USA and other migrant des…
  • College: College of Medicine (COM)
  • Inventors: McGwire, Bradford
  • Licensing Officer: Dahlman, Jason "Jay"

Translational Activators of the Glutamate Transporter EAAT2 to Treat Neurological and Psychiatric Diseases
TS-043938 — Small molecule technology with novel translational activation mechanism.
Glutamate is a major neurotransmitter in the mammalian central nervous system (CNS) and essential for normal brain function including cognition, memory, and learning. However, the extracellular concentration of glutamate must remain below excitotoxic levels (~ 1 μM) to avoid overstimulation of …
  • College: College of Medicine (COM)
  • Inventors: Lin, Chien-Liang; Hodgetts, Kevin
  • Licensing Officer: Dahlman, Jason "Jay"

A Novel Vectored Vaccine Against Human Norovirus
TS-037664 — A live recombinant vesicular stomatitis virus (VSV)-vector vaccine composition for human norovirus.
Human norovirus (HuNoV) is a major causative agent of foodborne gastroenteritis worldwide. It is estimated that over 90% of outbreaks of acute nonbacterial gastroenteritis are caused by noroviruses. Healthcare facilities, including nursing homes and hospitals, are the most commonly reported place …
  • College: College of Food, Agricultural, and Environmental Sciences (CFAES)
  • Inventors: Li, Jianrong; Ma, Yuanmei
  • Licensing Officer: Dahlman, Jason "Jay"

Novel Vaccine for Respiratory Syncytial Virus
TS-037299 — Recombinant vesicular stomatitis virus (rVSV) vaccines to fight against respiratory syncytial virus (RSV) infections.
Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory tract illness (ALRI) in infants, children, and the elderly, and often leads to fatal bronchiolitis and pneumonia. About 3.4 million children under the age of five are hospitalized each year due to an acute RSV in…
  • College: College of Veterinary Medicine
  • Inventors: Niewiesk, Stefan; Binjawadagi, Basavaraj; Li, Jianrong; Peeples, Mark
  • Licensing Officer: Dahlman, Jason "Jay"

Estrogen Receptor Beta Agonist Compounds
TS-015086 — Estrogen Receptor Beta Agonists for the treatment of breast, colon, and prostate cancers as well as inflammatory diseases.
There is a large emphasis on the need for novel and more effective cancer therapeutics, since there were nearly 600,000 cancer deaths in the United States in 2016 alone. One method for therapy of prostate, breast, and colon cancer that has been gaining traction is the targeting of estrogen recepto…
  • College: College of Pharmacy
  • Inventors: Tjarks, Werner; Bartunek, Petr; Sedlak, David
  • Licensing Officer: Dahlman, Jason "Jay"

miR-3151 and BAALC as a Target for Drug Therapy
TS-014895 — Identified gene target for treatment of human acute leukemia, brain tumors and melanoma
Treatment failure is one of the leading causes of death in patients with human acute leukemia, yet the cause of treatment failure is still largely unknown. Overexpression of the RNA gene miR-3151 and its host gene, Brain and Acute Leukemia, Cytplasmic (BAALC), is a sign of an ineffective treatment…
  • College: College of Medicine (COM)
  • Inventors: de la Chapelle, Albert; Eisfeld, Ann-Kathrin; Tanner, Stephan
  • Licensing Officer: Dahlman, Jason "Jay"

Attenuated Vaccines for Human Respiratory Viruses (hMVP, hRSV, hPIV3)
TS-014854 — A live attenuated vaccine that targets viral genome replication, virus assembly, and budding.
Paramyxoviruses are the leading causative agents of acute viral respiratory tract infections. Among the paramyxoviruses, human metapneumovirus (hMPV), human respiratory syncytial virus (hRSV), and human parainfluenza virus type 3 (hPIV3) account for more than 70% of acute viral respiratory disease…
  • College: College of Food, Agricultural, and Environmental Sciences (CFAES)
  • Inventors: Li, Jianrong; Zhang, Yu
  • Licensing Officer: Dahlman, Jason "Jay"

Loading icon